Koers Teva Pharmaceutical Industries Limited TEL AVIV STOCK EXCHANGE
Aandelen
TEVA
IL0006290147
Farmaceutische producten
Omzet 2024 * | 15,86 mld. 58,13 mld. 14,72 mld. | Omzet 2025 * | 16,28 mld. 59,7 mld. 15,11 mld. | Marktkapitalisatie | 15,82 mld. 57,99 mld. 14,68 mld. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | 420 mln. 1,54 mld. 390 mln. | Nettowinst (verlies) 2025 * | 743 mln. 2,72 mld. 690 mln. | EV/omzet 2024 * | 1,92 x |
Nettoschuld 2024 * | 14,62 mld. 53,61 mld. 13,57 mld. | Nettoschuld 2025 * | 12,12 mld. 44,43 mld. 11,25 mld. | EV/omzet 2025 * | 1,72 x |
K/w-verhouding 2024 * |
19,5
x | K/w-verhouding 2025 * |
15,1
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 90,57% |
Recentste transcriptie over Teva Pharmaceutical Industries Limited
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Richard Francis
CEO | Chief Executive Officer | 55 | 01-01-23 |
Eli Kalif
DFI | Director of Finance/CFO | 51 | 22-12-19 |
Eric Hughes
CTO | Chief Tech/Sci/R&D Officer | - | 01-08-22 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Gerald Lieberman
BRD | Director/Board Member | 77 | 01-09-15 |
Janet Vergis
BRD | Director/Board Member | 60 | 09-06-20 |
Sol Barer
CHM | Chairman | 76 | 01-01-15 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+33,46% | 701 mld. | |
+26,24% | 570 mld. | |
+0,93% | 381 mld. | |
+21,03% | 334 mld. | |
+17,51% | 322 mld. | |
+0,74% | 209 mld. | |
+2,95% | 212 mld. | |
-6,05% | 205 mld. | |
-3,61% | 157 mld. |